- Home
- DBL vs DRTS Comparison
DBL vs DRTS Comparison
Compare DBL & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBL
- DRTS
- Stock Information
- Founded
- DBL 2011
- DRTS 2015
- Country
- DBL United States
- DRTS Israel
- Employees
- DBL N/A
- DRTS N/A
- Industry
- DBL
- DRTS Medical/Dental Instruments
- Sector
- DBL
- DRTS Health Care
- Exchange
- DBL Nasdaq
- DRTS Nasdaq
- Market Cap
- DBL 296.0M
- DRTS 252.8M
- IPO Year
- DBL N/A
- DRTS N/A
- Fundamental
- Price
- DBL $15.30
- DRTS $3.08
- Analyst Decision
- DBL
- DRTS Strong Buy
- Analyst Count
- DBL 0
- DRTS 2
- Target Price
- DBL N/A
- DRTS $8.00
- AVG Volume (30 Days)
- DBL 61.0K
- DRTS 36.7K
- Earning Date
- DBL 01-01-0001
- DRTS 08-13-2025
- Dividend Yield
- DBL 8.67%
- DRTS N/A
- EPS Growth
- DBL N/A
- DRTS N/A
- EPS
- DBL N/A
- DRTS N/A
- Revenue
- DBL N/A
- DRTS N/A
- Revenue This Year
- DBL N/A
- DRTS N/A
- Revenue Next Year
- DBL N/A
- DRTS N/A
- P/E Ratio
- DBL N/A
- DRTS N/A
- Revenue Growth
- DBL N/A
- DRTS N/A
- 52 Week Low
- DBL $13.75
- DRTS $1.93
- 52 Week High
- DBL $15.70
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- DBL 39.43
- DRTS 59.10
- Support Level
- DBL $15.27
- DRTS $3.12
- Resistance Level
- DBL $15.37
- DRTS $3.35
- Average True Range (ATR)
- DBL 0.10
- DRTS 0.15
- MACD
- DBL -0.02
- DRTS 0.02
- Stochastic Oscillator
- DBL 14.29
- DRTS 70.00
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.